Frunevetmab (trade name: Frunevima) is a humanized monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is an IgG1 kappa immunoglobulin, which binds to the protein CD20 on the surface of B-cells and triggers their destruction. Frunevetmab is administered by intravenous infusion and is used in combination with other drugs such as rituximab and fludarabine. It has been approved by the US Food and Drug Administration (FDA) for the treatment of CLL and SLL in adult patients who have received at least one prior therapy.
Frunevetmab, sold under the brand name Solensia, is a medication used to treat pain associated with osteoarthritis in cats. It is the first monoclonal antibody new animal drug approved by the U.S. Food and Drug Administration for use in any animal species.
Frunevetmab is a cat-specific monoclonal antibody, a type of protein designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain. When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.
Here's a summary of Frunevetmab:
- Type of medication: Monoclonal antibody
- Brand name: Solensia
- Use: Alleviation of pain associated with osteoarthritis in cats
- Target: Nerve growth factor (NGF)
- How it works: Binds to NGF, preventing pain signal from reaching the brain